FDA Puts Idenix Hep C Drug On Hold Amid Bristol-Myers Woes

Law360, New York (August 27, 2012, 8:50 PM EDT) -- Idenix Pharmaceuticals Inc. on Monday said the U.S. Food and Drug Administration has temporarily blocked patients from using an experimental hepatitis C drug after the death of a clinical trial participant taking a similar medicine developed by Bristol-Myers Squibb Co.

The clinical hold announcement came less than two weeks after Massachusetts-based Idenix said a partial hold had been placed on another one of its emerging hepatitis C treatments because of FDA concerns about severe heart problems suffered by several participants in a Bristol-Myers clinical trial....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.